Natural Killer Cells in Older Patients With Acute Myeloid Leukemia

Descriptive Study Evaluating the Presence and Function of Natural Killer Cells in Elderly Patients With Acute Myeloid Leukemia in First Remission.

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00540956

Enrollment

Registered

2007-10-08

Start date

2006-11-30

Completion date

Unknown

Last updated

2011-05-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Leukemia

Keywords

untreated adult acute myeloid leukemia, adult acute megakaryoblastic leukemia (M7), adult acute minimally differentiated myeloid leukemia (M0), adult acute monoblastic leukemia (M5a), adult acute monocytic leukemia (M5b), adult acute myeloblastic leukemia with maturation (M2), adult acute myeloblastic leukemia without maturation (M1), adult acute myelomonocytic leukemia (M4), adult erythroleukemia (M6a), adult pure erythroid leukemia (M6b), adult acute myeloid leukemia with 11q23 (MLL) abnormalities, adult acute myeloid leukemia with inv(16)(p13;q22), adult acute myeloid leukemia with t(16;16)(p13;q22), adult acute myeloid leukemia with t(8;21)(q22;q22)

Brief summary

RATIONALE: Studying natural killer cells in samples of blood from patients with cancer may help doctors find out how these cells are effected by chemotherapy. PURPOSE: This clinical trial is studying natural killer cells in older patients with acute myeloid leukemia.

Detailed description

OBJECTIVES: Primary * Determine the evolution of functional receptors of natural killer (NK) cells after completion of chemotherapy in elderly patients with acute myeloid leukemia in first remission. Secondary * Measure the kinetics of cytotoxic functional recovery of NK cells. * Determine activation markers of NK cells. OUTLINE: This is a multicenter study. Patients receive 1 course of consolidation therapy comprising an anthracycline and cytarabine to induce first remission. Blood is collected on day 0 of the consolidation course and then every 2 weeks for 8 weeks.

Interventions

DRUGcytarabine

OTHERlaboratory biomarker analysis

Study design

Primary purpose

TREATMENT

Masking

NONE

Eligibility

Sex/Gender

ALL

Age

65 Years to No maximum

Healthy volunteers

Inclusion criteria

DISEASE CHARACTERISTICS: * Diagnosis of acute myeloid leukemia * No promyelocytic leukemia * No prior therapy PATIENT CHARACTERISTICS: * Hemoglobin \> 10 g/dL PRIOR CONCURRENT THERAPY: * See Disease Characteristics

Design outcomes

Primary

Measure	Time frame
Evolution of functional natural killer (NK) cells after chemotherapy	—

Secondary

Measure	Time frame
Kinetics of NK cells	—
Activation markers of NK cells	—

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026